Ray Barlow, CEO of e-Therapeutics, who took over the new role on Thurdsay as announced on January 9, 2017, said thate-Therapeutics is at the forefront of a new wave of science.
Barlow was previously Executive Director of Corporate Development at Amgen Inc. based in Switzerland. e-Therapeutics expects to use Barlow’s experience of drug discovery, development and commercialization, acquired through regional and global roles in the biotech and pharmaceutical sector.
His previous responsibilities have included scientific, business and corporate roles with AstraZeneca, Crucell NV and Johnson and Johnson, and has created a unique, computational-based drug discovery platform. This platform uses a range of truly cutting-edge technologies, including artificial intelligence, said e-Therapeutics announcing the new boss’s arrival.
“I am convinced of the value in the platform and our differentiated approach to drug discovery, which should allow us and potential partners to more efficiently discover more effective drug treatments,” said Barlow.
He said that his near-term aim is to ensure the company’s resources are appropriately focused on activities that are of the greatest commercial potential. “As part of this process, I am looking forward to engaging with our key stakeholders as well as subsequently positioning and promoting the Company to an industry which needs the assets and solutions we can provide,” Barlow concluded.